SXTCHealthcare · Drug Manufacturers - Specialty & Generic

SXTC Stock Forecast: China Sxt Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 31 July 2026

$0.06

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap

$2.4M

Ticker Nerd rank

8 / 100

Median analyst target

—

Analysts covering

—

Ticker Nerd rank

SXTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores China Sxt Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

8 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Revisions

Quality

Volatility

Momentum

Issuance

Value

Size (99): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own China Sxt Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

SXTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SXTC, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

SXTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

China Sxt Pharmaceuticals, Inc. (SXTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 2.1×
Price / book: 0.0×
EV / EBITDA: 3.6×

Growth & margins

Revenue growth (YoY): −43.9%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −153.3%
Net margin: 21.9%

Returns & dividend

Return on equity: −27.5%
Return on assets: −15.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SXTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
SXTCChina Sxt Pharmaceuticals, Inc.	$2.4M	8
UPCUniverse Pharmaceuticals, Inc.	$2.0M	29
SHPHShuttle Pharmaceuticals Holdings, Inc.	$2.4M	16
SBFMSunshine Biopharma, Inc.	$2.8M	43
PRFXPRF Technologies Ltd.	$3.0M	3
IMCCIM Cannabis Corp.	$1.0M	23
INMInMed Pharmaceuticals, Inc.	$4.9M	22

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SXTC appears on the weeks it earns a place.

News

Latest SXTC news & analysis

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

GlobeNewsWire · 24 July 2026positive

Univest Securities, LLC announced the closing of a registered direct offering worth approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC), described as a China-based innovative pharmaceutical company focused on traditional Chinese medicine pieces.

Why it matters — The completion of this $9 million offering indicates SXTC has secured additional capital through a registered direct placement, which may impact the company's financial position.

FAQ

Frequently asked questions about SXTC stock

How does Ticker Nerd's model rank SXTC?

As at 1 Aug 2026, China Sxt Pharmaceuticals, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the SXTC stock forecast for 2030?

No analyst covering China Sxt Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTC are extrapolating price history, which says nothing about the business.

What does China Sxt Pharmaceuticals, Inc. do?

What is the latest news on SXTC?

The most recent item we track (GlobeNewsWire, 24 July 2026): "Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)". Univest Securities, LLC announced the closing of a registered direct offering worth approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC), described as a China-based innovative pharmaceutical company focused on traditional Chinese medicine pieces.

Company

About China Sxt Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc. is a pharmaceutical company specializing in the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), including advanced, fine, and regular varieties under the historic 'Su Xuangtang' brand with nearly 280 years of heritage. Based in Taizhou, Jiangsu Province, China, the company blends ancient TCM traditions with modern production techniques, adhering to Good Manufacturing Practices (GMP) to ensure quality, safety, and efficacy in products like TCM granules tailored for hospitals and pharmacies. Established in 2005, it has pursued innovation through substantial R&D investments, including 13 invention patent applications and leadership from Chief Scientific Officer Dr. Jingzhen Deng, who drives strategies for non-decocting, advanced TCMP using aqueous extraction ratios, fingerprint analysis, and bioactive compound quantization. Key milestones include a 2019 strategic partnership with Zhangtai Group for product expansion, ongoing distribution network growth, and production enhancements to meet rising TCM demand. Operating primarily in China's domestic market via a Variable Interest Entity structure, China SXT Pharmaceuticals occupies a niche in the TCM sector, holding about 3% market share among competitors and capitalizing on increasing interest in alternative medicines. Its focus on rigorous quality control and modernization positions it within the evolving pharmaceutical landscape.

CEO Mr. Feng Zhou · 56 employees · China · https://www.sxtchina.com